RXi Licenses shRNAi Technology From Cold Spring Harbor Lab | GenomeWeb
NEW YORK (GenomeWeb News) – CytRx subsidiary RXi Pharmaceuticals has licensed short hairpin RNAi technology from Cold Spring Harbor Laboratory, CytRX said today.
 
Under the licensing agreement, RXi purchased a worldwide, non-exclusive license to the technology, which was developed by Cold Spring Harbor’s Gregory Hannon.
 
Hannon is a co-founder and member of RXi’s scientific advisory board.
 
Financial terms of the agreement were not released.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.